Better Therapeutics- Tradeable Rights - March 2021 Net Income

As of the most recent data (September 2023), MCADR shows a net income of $-32M. That compares with $-45M in the prior-year period — up 30.2% year over year. That is below the sector sector average of $98M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MCADR's net income is now $-32M (was $-45M) — a 30.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Better Therapeutics- Tradeable Rights - March 2021 is outperforming or lagging.

The its sector sector average net income is about $98M. Better Therapeutics- Tradeable Rights - March 2021 is at $-32M, which is lower that average. That is roughly 132.3% below the sector mean. Use the comparison chart on this page to see how MCADR stacks up against individual peers as well.

Tracking MCADR's net income over time shows whether Better Therapeutics- Tradeable Rights - March 2021 is scaling, shrinking, or reshaping that part of the business. The current reading is $-32M That compares with $-45M in the prior-year period — up 30.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has Better Therapeutics- Tradeable Rights - March 2021's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-32M) with ownership activity and broader fundamentals.